The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing-Remitting and Secondary Progressive Multiple Sclerosis.
Journal
Drugs in R&D
ISSN: 1179-6901
Titre abrégé: Drugs R D
Pays: New Zealand
ID NLM: 100883647
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
accepted:
11
07
2023
medline:
27
11
2023
pubmed:
29
8
2023
entrez:
28
8
2023
Statut:
ppublish
Résumé
Multiple sclerosis (MS) is a chronic neurodegenerative disease that affects the central nervous system (CNS). Currently, MS treatment is limited to several Food and Drug Administration (FDA)- and European Medicines Agency (EMA)-approved medications that slow disease progression by immunomodulatory action. Fingolimod and siponimod have similar mechanisms of action, and consequently, their therapeutic effects may be comparable. However, while fingolimod is mainly used for relapsing-remitting MS (RRMS), siponimod, according to EMA label, is recommended for active secondary progressive MS (SPMS). Clinicians and scientists are analysing whether patients can switch from fingolimod to siponimod and identifying the advantages or disadvantages of such a switch from a therapeutic point of view. In this review, we aim to discuss the therapeutic effects of these two drugs and the advantages/disadvantages of switching treatment from fingolimod to siponimod in patients with the most common forms of MS, RRMS and SPMS.
Identifiants
pubmed: 37640862
doi: 10.1007/s40268-023-00434-6
pii: 10.1007/s40268-023-00434-6
pmc: PMC10676342
doi:
Substances chimiques
Fingolimod Hydrochloride
G926EC510T
siponimod
RR6P8L282I
Immunosuppressive Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
331-338Subventions
Organisme : Charles University in Prague, Czech Republic
ID : Cooperatio Program
Organisme : Charles University in Prague, Czech Republic
ID : research area NEUR
Organisme : grant projects of the Ministry of Health of the Czech Republic
ID : FN HK 00179906
Informations de copyright
© 2023. The Author(s).
Références
Biomedicines. 2019 Jul 29;7(3):
pubmed: 31362384
JAMA Neurol. 2016 Sep 1;73(9):1089-98
pubmed: 27380540
Mult Scler. 2018 Oct;24(11):1421-1432
pubmed: 28752787
Mult Scler. 2011 Aug;17(8):939-48
pubmed: 21459808
Biochem Pharmacol. 2021 Apr;186:114465
pubmed: 33577891
Neurol Neuroimmunol Neuroinflamm. 2022 Mar 30;9(3):
pubmed: 35354603
Drugs. 2017 Oct;77(16):1755-1768
pubmed: 28905255
Front Immunol. 2019 Jan 10;9:3116
pubmed: 30687321
Neurology. 2020 Jun 16;94(24):1088-1092
pubmed: 32471886
CNS Drugs. 2021 Apr;35(4):385-402
pubmed: 33797705
Drug Des Devel Ther. 2017 Nov 02;11:3153-3157
pubmed: 29138536
Cell J. 2017 Apr-Jun;19(1):1-10
pubmed: 28367411
Nutr Rev. 2017 Sep 1;75(9):673-682
pubmed: 28938796
Pharmacol Ther. 2018 May;185:34-49
pubmed: 29127024
Curr Med Res Opin. 2021 Nov;37(11):1933-1944
pubmed: 34384311
Drugs. 2019 Jun;79(9):1009-1015
pubmed: 31144287
Drugs. 2014 Aug;74(12):1411-33
pubmed: 25063048
J Neuroinflammation. 2016 Feb 08;13:31
pubmed: 26856814
Ann Neurol. 2011 May;69(5):759-77
pubmed: 21520239
Nat Rev Neurol. 2012 Nov 5;8(11):647-56
pubmed: 23007702
J Clin Med. 2022 Oct 13;11(20):
pubmed: 36294354
Lancet. 2018 Mar 31;391(10127):1263-1273
pubmed: 29576505
Neurol Sci. 2022 Jun;43(6):3565-3581
pubmed: 35243548
J Neuroinflammation. 2016 Aug 26;13(1):207
pubmed: 27566665
Ther Adv Neurol Disord. 2023 Jan 24;16:17562864221146836
pubmed: 36710720
Lancet Neurol. 2018 Feb;17(2):162-173
pubmed: 29275977
Ther Clin Risk Manag. 2016 Feb 19;12:261-72
pubmed: 26929636
Neurol Sci. 2021 Nov;42(11):4837-4838
pubmed: 34390419
CNS Drugs. 2020 Nov;34(11):1191-1200
pubmed: 33108633
Neurol Neurochir Pol. 2018 Jan - Feb;52(1):98-101
pubmed: 29110882
Pharmacoeconomics. 2021 May;39(5):563-577
pubmed: 33791945
Front Immunol. 2020 Apr 08;11:635
pubmed: 32322257
Eur J Neurol. 2018 Oct;25(10):1270-1275
pubmed: 29851435
Mol Pharmacol. 2016 Jan;89(1):176-86
pubmed: 26494861
Neuropharmacology. 2017 Feb;113(Pt B):597-607
pubmed: 27825807
Neurology. 2014 Jul 15;83(3):278-86
pubmed: 24871874
J Med Econ. 2022 Jan-Dec;25(1):669-678
pubmed: 35575251
Neurotherapeutics. 2017 Oct;14(4):859-873
pubmed: 28812220
Neurol Clin Pract. 2014 Oct;4(5):402-409
pubmed: 29443255
Curr Opin Lipidol. 2022 Jun 1;33(3):199-207
pubmed: 35695616
Drugs. 2021 Feb;81(2):207-231
pubmed: 33289881
J Neurol. 2016 Mar;263(3):606-10
pubmed: 26914924
Mult Scler Relat Disord. 2019 Nov;36:101335
pubmed: 31557679
Syst Rev. 2021 Oct 28;10(1):280
pubmed: 34711264
J Cell Mol Med. 2015 Jul;19(7):1729-34
pubmed: 25864579
Lancet Neurol. 2015 Apr;14(4):406-19
pubmed: 25792099
PLoS One. 2020 Feb 3;15(2):e0228380
pubmed: 32012202
Lancet. 2016 Mar 12;387(10023):1075-1084
pubmed: 26827074
Semin Neurol. 2013 Feb;33(1):37-44
pubmed: 23709211
eNeurologicalSci. 2021 May 15;23:100346
pubmed: 34041374
Int J Mol Sci. 2020 Oct 13;21(20):
pubmed: 33066042
Mult Scler. 2022 Dec;28(14):2243-2252
pubmed: 35971322
Neural Regen Res. 2019 Nov;14(11):1950-1960
pubmed: 31290453
Nat Rev Mol Cell Biol. 2018 Mar;19(3):175-191
pubmed: 29165427
Am J Manag Care. 2016 Jun;22(6 Suppl):s159-70
pubmed: 27356025
Lancet Neurol. 2013 Aug;12(8):756-67
pubmed: 23764350
Neurology. 2021 Aug 31;97(9):e869-e880
pubmed: 34193589
Pharm Res. 2008 Aug;25(8):1737-50
pubmed: 18058202
Cells. 2020 Jul 24;9(8):
pubmed: 32722245
Glia. 2010 Sep;58(12):1465-76
pubmed: 20648639
Nat Rev Immunol. 2022 Dec;22(12):734-750
pubmed: 35508809
Mult Scler J Exp Transl Clin. 2021 Nov 03;7(4):20552173211049168
pubmed: 34777855
Cochrane Database Syst Rev. 2021 Nov 16;11:CD013647
pubmed: 34783010
Expert Opin Investig Drugs. 2019 Dec;28(12):1051-1057
pubmed: 31603362